CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.

Sophie Archer Phillip M Brailey Minjung Song Phillip D Bartlett Ines Figueiredo Bora Gurel Christina Guo Verena Brucklacher-Waldert H Lorraine Thompson Jude Akinwale Samantha E Boyle Christine Rossant Neil R Birkett Julia Pizzey Mark Maginn James Legg Richard Williams Colette M Johnston Philip Bland-Ward Johann S de Bono Andrew J Pierce

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

CB307 is a first-in-class immunotherapeutic that triggers potent PSMA-dependent T-cell activation, thereby alleviating toxicologic concerns against unrestricted CD137 agonism.

Keyphrases

pet ct
pet imaging
positron emission tomography
cancer therapy
nk cells